EP3589315A4 - Zusammensetzungen und verfahren zur induzierung von hiv-1-antikörpern - Google Patents

Zusammensetzungen und verfahren zur induzierung von hiv-1-antikörpern Download PDF

Info

Publication number
EP3589315A4
EP3589315A4 EP18760878.1A EP18760878A EP3589315A4 EP 3589315 A4 EP3589315 A4 EP 3589315A4 EP 18760878 A EP18760878 A EP 18760878A EP 3589315 A4 EP3589315 A4 EP 3589315A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
compositions
methods
inducing hiv
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18760878.1A
Other languages
English (en)
French (fr)
Other versions
EP3589315A1 (de
Inventor
Barton F. Haynes
Kevin O. SAUNDERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/020823 external-priority patent/WO2017152146A2/en
Application filed by Duke University filed Critical Duke University
Publication of EP3589315A1 publication Critical patent/EP3589315A1/de
Publication of EP3589315A4 publication Critical patent/EP3589315A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18760878.1A 2017-03-03 2018-03-02 Zusammensetzungen und verfahren zur induzierung von hiv-1-antikörpern Pending EP3589315A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2017/020823 WO2017152146A2 (en) 2016-03-03 2017-03-03 Compositions and methods for inducing hiv-1 antibodies
US201862624620P 2018-01-31 2018-01-31
PCT/US2018/020788 WO2018161049A1 (en) 2017-03-03 2018-03-02 Compositions and methods for inducing hiv-1 antibodies

Publications (2)

Publication Number Publication Date
EP3589315A1 EP3589315A1 (de) 2020-01-08
EP3589315A4 true EP3589315A4 (de) 2021-06-23

Family

ID=63371208

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18760878.1A Pending EP3589315A4 (de) 2017-03-03 2018-03-02 Zusammensetzungen und verfahren zur induzierung von hiv-1-antikörpern

Country Status (3)

Country Link
EP (1) EP3589315A4 (de)
CA (1) CA3055204A1 (de)
WO (1) WO2018161049A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3016327A1 (en) 2016-03-01 2017-09-08 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies
EP3423091A4 (de) 2016-03-03 2019-10-30 Duke University Zusammensetzungen und verfahren zur induzierung von hiv-1-antikörpern
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (de) 2016-10-03 2020-07-08 Duke University Verfahren zur identifizierung von immunogenen durch targeting unwahrscheinlicher mutationen
CA3092925A1 (en) * 2018-03-02 2019-09-06 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
WO2020072169A1 (en) 2018-10-01 2020-04-09 Duke University Hiv-1 envelope stabilizing mutations
CA3115232A1 (en) * 2018-10-01 2020-04-09 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
CN119241692A (zh) * 2018-12-04 2025-01-03 洛克菲勒大学 Hiv疫苗免疫原
WO2022087031A1 (en) * 2020-10-19 2022-04-28 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
US20240197854A1 (en) * 2021-01-28 2024-06-20 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
CA3211186A1 (en) * 2021-03-08 2022-09-15 Kevin SAUNDERS Hiv-1 envelope glycopeptide nanoparticles and their uses
EP4415751A4 (de) * 2021-10-11 2025-10-08 Univ Duke Zusammensetzungen mit hiv-hüllen zur induktion von hiv-1-antikörpern
WO2025245259A2 (en) * 2024-05-21 2025-11-27 Dana-Farber Cancer Institute, Inc. Hiv-1 immunogen compositions and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043386A1 (en) * 2012-09-12 2014-03-20 Duke University Clonal lineage antibodies
WO2015153638A1 (en) * 2014-03-31 2015-10-08 Duke University Compositions comprising ch848 envelopes and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127108A1 (en) 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043386A1 (en) * 2012-09-12 2014-03-20 Duke University Clonal lineage antibodies
WO2015153638A1 (en) * 2014-03-31 2015-10-08 Duke University Compositions comprising ch848 envelopes and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. P. WEST ET AL: "Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 30, 24 July 2012 (2012-07-24), pages E2083 - E2090, XP055166144, ISSN: 0027-8424, DOI: 10.1073/pnas.1208984109 *
FLORIAN KLEIN ET AL: "Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization", CELL, vol. 153, no. 1, 1 March 2013 (2013-03-01), pages 126 - 138, XP055119651, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.03.018 *
H. MOUQUET ET AL: "Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 47, 30 October 2012 (2012-10-30), pages E3268 - E3277, XP055068116, ISSN: 0027-8424, DOI: 10.1073/pnas.1217207109 *
HUA-XIN LIAO ET AL: "Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus", NATURE, vol. 496, no. 7446, 3 April 2013 (2013-04-03), London, pages 469 - 476, XP055226788, ISSN: 0028-0836, DOI: 10.1038/nature12053 *
See also references of WO2018161049A1 *

Also Published As

Publication number Publication date
WO2018161049A8 (en) 2018-10-04
CA3055204A1 (en) 2018-09-07
EP3589315A1 (de) 2020-01-08
WO2018161049A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
EP3589315A4 (de) Zusammensetzungen und verfahren zur induzierung von hiv-1-antikörpern
IL265844A (en) Anti-lag-3 antibodies and preparations
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
IL262176A (en) Anti-tim-3 antibodies and preparations
EP3585433A4 (de) Therapeutische zusammensetzungen und verwandte verfahren zur photoimmuntherapie
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
EP3442543A4 (de) Zusammensetzungen und verfahren für neurogenese
EP3268050A4 (de) Porenbildende proteinkonjugatzusammensetzungen und verfahren
EP3242940A4 (de) Verfahren und zusammensetzungen für kombinationsimmuntherapie
EP3286213A4 (de) Verfahren und zusammensetzungen für eine kombinationsimmuntherapie
EP3341021A4 (de) Anti-alk-antikörper und verfahren zur verwendung davon
EP3129048A4 (de) Antikörper, pharmazeutische zusammensetzungen und verwendungen davon
EP3253403A4 (de) Verfahren und zusammensetzungen für verbesserte kognition
EP3253389A4 (de) Apilimodzusammensetzungen und verfahren zur verwendung davon
TWI799417B (zh) 生物製藥組成物及相關方法
EP3113774A4 (de) Grapiprantzusammensetzungen und verfahren zur verwendung davon
EP3288542A4 (de) Zusammensetzungen und verfahren zur verabreichung von antikörpern
EP3513189A4 (de) Verfahren und zusammensetzungen zum t-zell-epitop-screening
EP3612230A4 (de) Palbociclib-zusammensetzungen und verfahren dafür
EP3172230A4 (de) Zusammensetzungen und verfahren zur abzielung auf das tensidprotein eines rezeptors
EP3204120A4 (de) Verfahren und zusammensetzungen zur erhöhung der wirksamkeit von antimykotika
HK40046593A (en) Compositions and methods comprising anti-nrp2 antibodies
HK40005864A (en) Anti-lag-3 antibodies and compositions
HK40030990A (en) Anti-cxcr5 antibodies and compositions and uses thereof
HK40014724A (en) Compositions and methods for immunooncology

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20201216BHEP

Ipc: C07K 14/16 20060101ALI20201216BHEP

Ipc: A61K 39/12 20060101AFI20201216BHEP

Ipc: A61K 9/127 20060101ALI20201216BHEP

Ipc: C12Q 1/68 20180101ALI20201216BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039210000

Ipc: A61K0039120000

A4 Supplementary search report drawn up and despatched

Effective date: 20210520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101AFI20210514BHEP

Ipc: A61K 9/127 20060101ALI20210514BHEP

Ipc: C07K 14/16 20060101ALI20210514BHEP

Ipc: C12Q 1/68 20180101ALI20210514BHEP

Ipc: A61P 31/18 20060101ALI20210514BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230116

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231102